Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $4.04
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 13, 26 | Morgan Stanley |
Daily · Wilder smoothing
| maintain |
| Equal Weight |
| Equal Weight |
| Mar 9, 26 | Evercore ISI Group | maintain | Outperform | Outperform |
| Apr 11, 25 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Aug 13, 24 | Morgan Stanley | upgrade | Underweight | Equal Weight |
| Aug 10, 23 | JP Morgan | downgrade | Neutral | Underweight |
| Mar 16, 23 | JP Morgan | maintain | Neutral | Neutral |
| Jan 27, 23 | SVB Leerink | maintain | Market Perform | Market Perform |
| Jan 24, 23 | Morgan Stanley | maintain | Underweight | Underweight |
| Aug 15, 22 | Morgan Stanley | maintain | Underweight | Underweight |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 24.60 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 4.49 | Oscillator | Buy |
| Williams %R (14) | -91.54 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.30 (Hist -0.09) | Oscillator | Strong Sell |
| Average Directional Index (14) | 31.38 (+DI 10.7 / -DI 37.2) | Trend | Strong Sell |
| EMA 20 | 4.67 | MA | Strong Sell |
| SMA 20 | 4.79 | MA | Strong Sell |
| EMA 50 | 4.93 | MA | Strong Sell |
| SMA 50 | 5.15 | MA | Strong Sell |
| SMA 200 | 4.91 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | AVIR | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.9x | -0.5x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -2.0x | EPS est. -1.99 | In line |
| Price / Book | 1.6x | 0.8x | Elevated |
| Price / Sales | — | 0.4x | Discount |
| EV / EBITDA | -1.4x | -0.4x | Elevated |
| Return on equity | -64.2% | — | Weak |
| Gross margin | 0.0% | 10.5% | Below hist. |
| Debt / Equity | 0.00 | 0.00 | Conservative |
| Piotroski / Altman Z | 2/9 | Z 1.89 | Grey zone |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 18, 26 | Lucidi Bruno | director | M-Exempt | 29,600 | — |
| Jun 18, 26 |
| Lucidi Bruno |
| director |
| A-Award |
| 37,700 @ $4.36 |
| $164.4K |
| Jun 18, 26 | Lucidi Bruno | director | A-Award | 26,700 | — |
| Jun 18, 26 | Lucidi Bruno | director | M-Exempt | 29,600 | — |
| Jun 18, 26 | Berger Franklin M | director | M-Exempt | 29,600 | — |
| Jun 18, 26 | Berger Franklin M | director | A-Award | 37,700 @ $4.36 | $164.4K |
| Jun 18, 26 | Berger Franklin M | director | A-Award | 26,700 | — |
| Jun 18, 26 | Berger Franklin M | director | M-Exempt | 29,600 | — |
Stock news · updated daily
Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 12:20 p.m.
BlackRock Inc. purchased a new position in Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 8,720,077 shares of the company's stock, valued at approximately $40,548,000. BlackRock Inc. owned about 10.90% of Atea Pharmaceuticals as of its
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
Atea Pharmaceuticals NASDAQ: AVIR reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints against the standard-of-care regimen sofosbuvir/velpatasvir, marketed as Epclusa.
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2026, and to provide a business update.
Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ® ), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in a Global Phase 3 Program of Hepatitis C Virus (HCV) Treatments
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -0.56 | -0.41 | Beat 26.1% | — |
| May 12, 2026 | -0.60 | -0.57 | Beat 5.0% | — |
| Mar 5, 2026 | -0.49 | -0.57 | Miss -16.3% | — |
| Nov 12, 2025 | -0.46 | -0.53 | Miss -15.2% | — |
| Aug 7, 2025 | -0.46 | -0.44 | Beat 4.3% | — |
| May 12, 2025 | -0.56 | -0.40 | Beat 28.6% | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13G | Oct 6, 2026 | 2026-10-06 18:20:37 | View |
| 10-Q | Aug 12, 2026 | 2026-08-12 16:45:36 | View |
| 8-K | Aug 12, 2026 | 2026-08-12 16:15:36 | View |
| 4 | Jun 23, 2026 | 2026-06-23 17:00:20 | View |
| 4 | Jun 23, 2026 | 2026-06-23 17:00:17 | View |
| 4 | Jun 23, 2026 | 2026-06-23 17:00:12 | View |
| 4 | Jun 23, 2026 | 2026-06-23 17:00:09 | View |
| 4 | Jun 23, 2026 | 2026-06-23 17:00:08 | View |
| 4 | Jun 23, 2026 | 2026-06-23 17:00:06 | View |
| 4 | Jun 23, 2026 | 2026-06-23 17:00:04 | View |
Proxy statement (DEF 14A) disclosures